Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
ALNY's portfolio of rare disease and cardiovascular drugs is boosting revenues and reducing reliance on Amvuttra.
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NOVATO, Calif., Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ:RARE ) today announced the appointment of Eric Olson as chief business officer ( CBO ) and executive vice president effective September 22, 2025, following the planned retirement of Thomas Kassberg.
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President
NOVATO, Calif., Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) today announced the appointment of Eric Olson as chief business officer ( CBO ) and executive vice president effective September 22, 2025, following the planned retirement of Thomas Kassberg.
$1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth This Much Today - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Alnylam Pharmaceuticals ( NASDAQ: ALNY ) has outperformed the market over the past 5 years by 10.45% on an annualized basis producing an average annual return of 25.22%. Currently, Alnylam Pharmaceuticals has a market capitalization of $57.78 billion.
What's Going On With Intellia Therapeutics Stock Thursday - Intellia Therapeutics ( NASDAQ:NTLA )
Intellia Therapeutics Inc. ( NASDAQ: NTLA ) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran ( nex-z ) for the treatment of hereditary ATTR amyloidosis with polyneuropathy ( ATTRv-PN ) .
Why Alnylam Pharmaceuticals ( ALNY ) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is SPDR S&P Biotech ETF ( XBI ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Alnylam ( ALNY ) Surges 6.0%: Is This an Indication of Further Gains?
Alnylam (ALNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Alnylam Pharmaceuticals ALNY has outperformed the market over the past 10 years by 3.04% on an annualized basis producing an average annual return of 15.62%. Currently, Alnylam Pharmaceuticals has a market capitalization of $58.59 billion.
Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?
Alnylam's strong drug sales and advancing partnerships with Regeneron and Roche highlight key growth drivers in the quarters ahead.
Are Options Traders Betting on a Big Move in Alnylam Pharmaceuticals Stock?
Investors need to pay close attention to Alnylam Pharmaceuticals stock based on the movements in the options market lately.
$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Alnylam Pharmaceuticals ALNY has outperformed the market over the past 15 years by 13.35% on an annualized basis producing an average annual return of 25.78%. Currently, Alnylam Pharmaceuticals has a market capitalization of $57.85 billion.
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study.
Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
Basel, August 30, 2025 - Novartis today announced positive results from V-DIFFERENCE, a Phase IV study evaluating Leqvio® ( inclisiran ) compared to placebo, both administered on top of individually optimized lipid-lowering therapy ( LLT ) , in patients with high cholesterol ( ...
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
ALNY's Amvuttra revenues surge with 89% sales growth in H1 and a key label expansion, but faces tough competition in the ATTR-CM market.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is First Trust NYSE Arca Biotechnology ETF ( FBT ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily Living ( MG-ADL ) total score ...
A Closer Look at Alnylam Pharmaceuticals's Options Market Dynamics - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Financial giants have made a conspicuous bullish move on Alnylam Pharmaceuticals. Our analysis of options history for Alnylam Pharmaceuticals ALNY revealed 10 unusual trades. Delving into the details, we found 50% of traders were bullish, while 30% showed bearish tendencies.
How Is The Market Feeling About Alnylam Pharmaceuticals? - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Alnylam Pharmaceuticals's ALNY short percent of float has fallen 4.34% since its last report. The company recently reported that it has 3.24 million shares sold short, which is 3.31% of all regular shares that are available for trading.
Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Alnylam Pharmaceuticals ALNY has outperformed the market over the past 10 years by 2.77% on an annualized basis producing an average annual return of 14.61%. Currently, Alnylam Pharmaceuticals has a market capitalization of $56.09 billion.
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors - KalVista Pharmaceuticals ( NASDAQ:KALV ) , Metagenomi ( NASDAQ:MGX )
EMERYVILLE, Calif., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Metagenomi, Inc. MGX ( the "Company" ) , a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to ...
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should Invesco NASDAQ Next Gen 100 ETF ( QQQJ ) Be on Your Investing Radar?
Style Box ETF report for ...
Earnings Estimates Rising for Alnylam ( ALNY ) : Will It Gain?
Alnylam Pharmaceuticals (ALNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Alnylam Pharmaceuticals ALNY has outperformed the market over the past 15 years by 12.81% on an annualized basis producing an average annual return of 24.98%. Currently, Alnylam Pharmaceuticals has a market capitalization of $53.72 billion.
Are Medical Stocks Lagging ADC Therapeutics ( ADCT ) This Year?
Here is how ADC Therapeutics SA (ADCT) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year.
This Alnylam Pharmaceuticals Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday - Alamo Group ( NYSE:ALG ) , Apartment Inv & Mgmt ( NYSE:AIV )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. JP Morgan analyst Kenneth Worthington upgraded Federated Hermes, Inc.
Agios ( AGIO ) Q2 Revenue Jumps 45%
Agios Pharmaceuticals ( NASDAQ:AGIO ) , a biotechnology company focused on therapies for rare blood disorders, released its second quarter 2025 earnings on July 31, 2025. The headline was a notable revenue beat: This quarter showcased clear progress on sales for its lead product PYRUKYND, with ...
Why Is Alnylam Stock Gaining Friday? - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Amvuttra has reached 1,400 ATTR-CM patients, adding about $150 million in revenue. UBS raised Alnylam's price target to $550; Chardan sees it at $400. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily. Alnylam Pharmaceuticals Inc.
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
Alnylam stock jumps 15% after a surprise Q2 profit, driven by soaring Amvuttra sales and raised 2025 revenue guidance.
Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Q2 sales rose 17% Y/Y to $773.69 million, beating estimates of $638.55 million. Alnylam raised 2025 revenue guidance midpoint by 27% to $3.3 billion-$3.55 billion. The market's back, and these 3 income stocks are thriving. See them here→
Roblox, Carvana, eBay, C.H. Robinson Worldwide, Huntington Ingalls Industries And Other Big Stocks Moving Higher On Thursday - Alnylam Pharmaceuticals ( NASDAQ:ALNY ) , AGCO ( NYSE:AGCO )
U.S. stocks were higher, with the Nasdaq Composite gaining around 150 points on Thursday. Shares of Roblox Corporation RBLX rose sharply during Thursday's session after the company reported better-than-expected second-quarter sales results and raised its FY25 sales guidance.
Alnylam Pharmaceuticals ( ALNY ) Q2 Earnings and Revenues Beat Estimates
Alnylam (ALNY) delivered earnings and revenue surprises of +1,166.67% and +14.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
WALTHAM, Mass., July 31, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) , today announced its second quarter 2025 financial results and business highlights.
Regeneron ( REGN ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam Pharmaceuticals ( ALNY ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Alnylam Pharmaceuticals ALNY has outperformed the market over the past 15 years by 10.3% on an annualized basis producing an average annual return of 22.67%. Currently, Alnylam Pharmaceuticals has a market capitalization of $42.15 billion.
Alnylam ( ALNY ) Upgraded to Buy: What Does It Mean for the Stock?
Alnylam (ALNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Global Pharmaceutical Market Projected to Hit $2.2 Trillion by 2029
Boston, July 22, 2025 ( GLOBE NEWSWIRE ) -- According to the latest study from BCC Research, "Global Pharmaceutical Drugs Industry: Competitive Landscape 2023" is projected to reach $2.2 trillion by the end of 2029, with a CAGR of 5.5% for the forecast period of 2024-2029.
Is Invesco Biotechnology & Genome ETF ( PBE ) a Strong ETF Right Now?
Smart Beta ETF report for ...
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Autodesk ( NASDAQ:ADSK ) , Albertsons Companies ( NYSE:ACI )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. JP Morgan analyst Drew Chamberlain initiated coverage on Argan, Inc.
Is SPDR S&P Biotech ETF ( XBI ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Alnylam Pharma Stock Outlook: Is ALNY Topping Out? - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Alnylam Pharmaceuticals ALNY is currently in Phase 10 of its 18-phase Adhishthana Cycle. With this phase scheduled to end in September 2025, the stock remains within its bullish structure. If that structure holds, the peak is likely to form in Phase 11, the classic culmination point of the ...
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Alnylam Pharmaceuticals ALNY has outperformed the market over the past 5 years by 2.17% on an annualized basis producing an average annual return of 16.39%. Currently, Alnylam Pharmaceuticals has a market capitalization of $41.78 billion.
Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday - Apple ( NASDAQ:AAPL ) , Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. JP Morgan cut Apple Inc. AAPL price target from $240 to $230.
Is First Trust NYSE Arca Biotechnology ETF ( FBT ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Questex's Fierce Pharma Unveils Powerhouse Conference Program for the Inaugural Fierce Pharma Week, Where Pharma's Future Takes Shape
Unites Pharma Marketing, PR & Communications, New Product Planning & Commercialization, and Medical Affairs Communities; Thought Leaders from AbbVie, AstraZeneca, BMS, GSK, Johnson & Johnson, NBCUniversal, Pfizer, Takeda and More Deliver Unparalleled Education
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Alnylam Pharmaceuticals ALNY has outperformed the market over the past 20 years by 12.09% on an annualized basis producing an average annual return of 20.51%. Currently, Alnylam Pharmaceuticals has a market capitalization of $39.93 billion.
Should You Invest in the SPDR S&P Biotech ETF ( XBI ) ?
Sector ETF report for ...
